Form 4: Halozyme Director Receives Annual Equity Grant
Statement of Changes in Beneficial Ownership
Director Barbara Gayle Duncan received an annual grant of 3,796 restricted stock units and 6,040 stock options as part of Halozyme Therapeutics' director compensation program.
Summary
- Director Barbara Gayle Duncan was granted 3,796 restricted stock units (RSUs) on May 5, 2026.
- The director also received an option to purchase 6,040 shares of common stock at an exercise price of $65.87.
- Both the RSUs and the stock options are scheduled to vest on the earlier of May 5, 2027, or the date of the next annual meeting of stockholders.
- The RSU grant is subject to a deferral election under the company's Directors Deferred Equity Compensation Plan.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- The equity grants align the director's interests with those of shareholders through long-term incentive compensation.
Negatives
- The issuance of new equity grants results in minor dilution to existing shareholders.
Risks
- The value of the granted equity is subject to market volatility and the future performance of Halozyme Therapeutics' stock price.
Future Outlook
The equity grants are standard annual compensation and do not provide specific forward-looking guidance regarding company operations or financial performance.
Industry Context
StockSavvy.ai notes that annual equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to ensure board member retention and alignment with shareholder interests.
Comparison to Industry Standards
- The grant structure is consistent with standard director compensation packages for mid-to-large cap biotechnology companies.
- Vesting periods of one year are typical for annual director equity awards in the industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Annual grant of equity to Director Barbara Gayle Duncan. | 05/05/2026 | Standard alignment of director interests with shareholders. |
Stakeholder Impact
- Shareholders experience minor dilution from the issuance of new equity.
Next Steps
- Vesting of the RSUs and stock options on May 5, 2027, or the date of the next annual meeting.
Key Dates
| Date | Description |
|---|---|
| 05/05/2026 | Date of the equity grant transaction. |
| 05/07/2026 | Date the Form 4 was signed and filed. |
| 05/05/2027 | Vesting date for the RSUs and stock options. |
| 05/05/2036 | Expiration date for the stock options. |
Keywords
Halozyme Therapeutics, HALO, Director Compensation, Form 4, Insider Trading, Equity Grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.